Pisani C, Deantonio L, Surico D, Brambilla M, Galla A, Ferrara E, Masini L, Gambaro G, Surico N, Krengli M
Department of Radiotherapy, University Hospital Maggiore della Carità, Novara, Italy.
Chair of Radiotherapy, Department of Translational Medicine, University of "Piemonte Orientale", Via Solaroli, 17, 28100, Novara, Italy.
Clin Transl Oncol. 2016 Sep;18(9):901-8. doi: 10.1007/s12094-015-1458-9. Epub 2015 Nov 25.
Modern multidisciplinary cancer treatments aim at obtaining minimal influence on patients' quality of life (QoL). The purpose of this study was to assess QoL and correlate it with dose-volume parameters of organ at risks (OARs) in patients who received adjuvant radiotherapy for endometrial and cervical cancers.
We administered the EORTC QLQ-C30 and EN24 or CX24 questionnaires to 124 patients, 100 with endometrial cancer and 24 with cervical cancer treated with postoperative radiotherapy ± chemotherapy in regular follow-up. Bladder function, fecal incontinence or urgency and sexual functioning were investigated and correlated with dose-volume parameters of OAR by multiple linear regression analysis. This correlation was assessed by R (2) value.
QoL was very high in the majority of patients (82.3 % of patients). Few patients referred urinary incontinence (3.2 %) or abdominal discomfort of high grade (4.0 %). We found a significant correlation between bladder V40, i.e., absolute percentage of bladder volume that received a dose of 40 Gy, and global health status (p < 0.05, R (2) = 0.17), urinary urgency (p < 0.05, R (2) = 0.24), urinary incontinence (p < 0.05, R (2) = 0.23) and dyspareunia (p < 0.05, R (2) = 0.04). We found also a correlation between global health status and mean dose to vagina (p < 0.05, R (2) = 0.17) and between maximum dose to lumbo-sacral plexus and abdominal pain (p < 0.05, R (2) = 0.07).
Women treated with surgery and adjuvant radiotherapy for endometrial and cervical cancers have good QoL with minimal limitations of daily activities. QoL was correlated with dose-volume parameters such as bladder V40, mean dose to vagina, maximum dose to trigone and LSP.
现代多学科癌症治疗旨在对患者生活质量(QoL)产生最小影响。本研究的目的是评估接受子宫内膜癌和宫颈癌辅助放疗患者的生活质量,并将其与危及器官(OARs)的剂量体积参数相关联。
我们对124例患者进行了欧洲癌症研究与治疗组织QLQ-C30问卷以及EN24或CX24问卷的调查,其中100例为子宫内膜癌患者,24例为宫颈癌患者,这些患者均接受了术后放疗±化疗,并进行定期随访。对膀胱功能、大便失禁或急迫感以及性功能进行了调查,并通过多元线性回归分析将其与OAR的剂量体积参数相关联。这种相关性通过R(2)值进行评估。
大多数患者的生活质量非常高(82.3%的患者)。很少有患者提及尿失禁(3.2%)或重度腹部不适(4.0%)。我们发现膀胱V40(即接受40 Gy剂量的膀胱体积绝对百分比)与总体健康状况(p < 0.05,R(2) = 0.17)、尿急(p < 0.05,R(2) = 0.24)、尿失禁(p < 0.05,R(2) = 0.23)以及性交困难(p < 0.05,R(2) = 0.04)之间存在显著相关性。我们还发现总体健康状况与阴道平均剂量(p < 0.05,R(2) = 0.17)之间以及腰骶丛最大剂量与腹痛(p < 0.05,R(2) = 0.07)之间存在相关性。
接受子宫内膜癌和宫颈癌手术及辅助放疗的女性生活质量良好,日常活动受限极小。生活质量与剂量体积参数相关,如膀胱V40、阴道平均剂量、三角区最大剂量和腰骶丛。